From the links posted... note production volume mentioned...
2022! That is the target for the market launch Ensovibep. Together with Molecular Partners from Schlieren (Zurich), Novartis has developed the drug SKO136 (Ensovibep) for the treatment of Covid 19 patients. Phase II trial data show promising results and we are very pleased that we will manufacture SKO136 here at the Stein Large Molecules site in the future. We anticipate a large production volume in 2022 and 2023.
Ensovibep will make MOLN a $10 billion company, which means $300/share. Let's wait and see!
s
Short attack removed my Forbes post showing the mechanism of action. Bet they are the same one's shorting after hours. Just think of a Novartis announcement tomorrow saying they filed. A huge company like that could have protein mfg up to snuff in no time. No doubt the technology transfer is well past complete. The potential for the most exquisite pain for shorts is withing striking distance. Great news on a flat market day will make it impossible for them to achieve a breakeven close on a MOLN squeeze.
A
I was with AstraZeneca, then a small company in oncology that got bought out because of a best in class drug we had. That situation was microscopic in comparison to what Molecular Partners may have. We were a US pharma company selling a Switzerland Pharma company drug. We sold more of the drug than the rest of the world combined. We got bought out by another much bigger company. We were shocked, because of how sudden it was.
The good news is, the Swiss are really good at pharma. Of the top ten pharmaceutical companies in the world, # 2 and # 5 Novartis are from tiny Switzerland. That's pretty amazing.
After the first data came out on the hamster trial, did you notice how quickly Novartis had a deal in place with Molecular Partners? The latest invitro data did not disappoint. Anything is possible here. The Swiss are not pumpers like a lot of other Pharma Companies. Molecular Partners could soon be in the news and on the world stage. With each new data release, the bet on this company gets better. Sometimes things knock drug outs at the last minute, but the potential here is literally world changing.
Two times today's price on a buyout, not likely. This company is not going to fold their hand right now, and go home without seeing all the cards they have. With every piece of good data they get, the value goes up. If the people that are evaluating the data remain confident in what they are seeing, they are not going to cash out for 2X. If they start losing confidence in what they are seeing, then Novartis will pull the plug. Sit back, relax and enjoy the show.
f
Bought yesterday. I think, Molecular Partners will have a bright future and is just started to rise!
m
There are three ways forward: 1: get Novartis deal (positive for the share price). 2. No deal and capital increase (shares will suffer a lot). 3 Takeover @ 40 - 50. I Expect one of the three to Happen this year. Probabilities: scenario 1: 50 %, scenario 2: 40 %, scenario 3: 10 %. Cash will be below 100 mm in 2022 without deals. Therefore the assumption that one of three scenarios will happen.
m
Novartis buyout @ 50 coming?
T
Is Molecular Partners vaccine technology for Covid more effective as the virus Mutates? Can it target more strains and turn out to be more effective than other vaccines if mutations continue? We now have a new strain from Japan, along with the African strain appearing in the last few weeks.
A
New german stock board. Die Biotechfirma Molecular Partners hat ein Therapieprogramm zur Bekämpfung von COVID-19 gestartet. Das Unternehmen hat künstliche Proteine entwickelt, welche das SARS-CoV-2-Virus neutralisieren sollen.
Seite 1 der Diskussion 'Molecular Partners grosse Hoffnung auf COVID-19 Medikament' vom 20.08.2020 im w:o-Forum 'Biotech'.
Seite 1 der Diskussion 'Molecular Partners grosse Hoffnung auf COVID-19 Medikament' vom 20.08.2020 im w:o-Forum 'Biotech'.
www.wallstreet-online.de
s
I've been looking at licensing deals for a long long time, and getting 22 percent is most excellent, all they need to do is kick back and collect the cash. Novartis is a behemoth monster of a company and they will handle everything! 10 billion dollar market cap is a forgone conclusion.
Y
MOLN reached a 52 Week low at 7.78
n
This stock is expected to deliver a best in class vaccine and the collaboration with Novartis is very promising
T
It's so lonely in here.... someone put the lights on please...
S
Market is missing how truly unique this 420 Covid therapeutic is.
s
Monoclonal Antibody sites in the USA: FDA asks for shut down because they are not effective against Omicron, the state of Florida for example is shutting them down MOLN's antibodies are effective against Omicron. Hopefully Novartis will file EUA soon.
f
Wow - new 52W high (not all time high as Yahoo Finance Insights says). The ATH should be about CHF 38.40 what is + CHF 10 from CHF 28.40. These are about 35% more to go from here... I think, a "real" new ATH will be reached (very) soon!
T
Anyone here
i
New from yesterday - Molecular Partners: ensovibep against Covid-19 evaluated by NIH in the US 15 Mar 2021 10:03 AM (adds details, analyst commentary and stock price)
Zurich (awp) - Molecular Partners announced on Monday that its experimental Covid-19 ensovibep pneumonia darpin (MP0420 not long ago) has been included in the Activ-3 program of Phase III clinical studies conducted by the National Institutes of Health (NIH) in the US. The aim of this project is to accelerate the therapeutic and vaccine response to the pandemic, the Zurich-based company said in a statement on Monday.
The ensovibep component will initially recruit 300 participants hospitalized with mild to moderate forms of Covid-19 and evaluate the experimental treatment against a placebo, in addition to current treatment standards in the United States, including Gilead's remdesivir. If the results are positive, the NIH plans to enroll an additional 700 patients.
The primary endpoint of this study is the time to sustained recovery over two weeks after hospital discharge.
Molecular Partners' tri-specific antiviral proteins are designed to neutralize the infectious capabilities of Sars-Cov-2. The Zurich-based laboratory asserts that their administration could be effective in both treating and preventing a viral infection.
The Schlieren-based company and its prestigious research partner Novartis recently stated that they had observed an acceptable safety and tolerability profile in a Phase I clinical study in healthy volunteers, with no significant undesirable side effects. A Phase II/III study is expected to be launched in the next three months.
The Swiss Federal Office of Public Health (SFOPH) has pre-ordered 3.2 million doses of ensovibep since August, subject to approval by Swissmedic.
The ups and downs of ensovibep's development are likely to be the main catalyst for Molecular Partners' share price again this year, anticipates Olav Zilian of Mirabaud Securities. The analyst points out that in an ideal world, as in management's hopes, the treatment could be approved in the United States before the end of December.
At 10:05 a.m., Molecular Partners shares were up 5.8% at 22.80 francs, on the provisional podium of an SPI up 0.61%.
https://assets.wallstreet-online.de/_media/8763/board/20220317153902-screenshot-2022-03-17-at-15-12-40-powerpoint-pres.png
#+#+
2022! That is the target for the market launch Ensovibep. Together with Molecular Partners from Schlieren (Zurich), Novartis has developed the drug SKO136 (Ensovibep) for the treatment of Covid 19 patients. Phase II trial data show promising results and we are very pleased that we will manufacture SKO136 here at the Stein Large Molecules site in the future. We anticipate a large production volume in 2022 and 2023.
https://www.mncjobs.ch/jobs/qa-operations-expert-stein-1047582
https://www.novartis.com/pk-en/careers/career-search/job-details/341084br/qa-operations-specialist
The good news is, the Swiss are really good at pharma. Of the top ten pharmaceutical companies in the world, # 2 and # 5 Novartis are from tiny Switzerland. That's pretty amazing.
After the first data came out on the hamster trial, did you notice how quickly Novartis had a deal in place with Molecular Partners? The latest invitro data did not disappoint. Anything is possible here. The Swiss are not pumpers like a lot of other Pharma Companies. Molecular Partners could soon be in the news and on the world stage. With each new data release, the bet on this company gets better. Sometimes things knock drug outs at the last minute, but the potential here is literally world changing.
Two times today's price on a buyout, not likely. This company is not going to fold their hand right now, and go home without seeing all the cards they have. With every piece of good data they get, the value goes up. If the people that are evaluating the data remain confident in what they are seeing, they are not going to cash out for 2X. If they start losing confidence in what they are seeing, then Novartis will pull the plug. Sit back, relax and enjoy the show.
I think, Molecular Partners will have a bright future and is just started to rise!
Die Biotechfirma Molecular Partners hat ein Therapieprogramm zur Bekämpfung von COVID-19 gestartet. Das Unternehmen hat künstliche Proteine entwickelt, welche das SARS-CoV-2-Virus neutralisieren sollen.
Molecular Partners grosse Hoffnung auf COVID-19 Medikament | wallstreet-online.de - Vollständige Diskussion unter:
https://www.wallstreet-online.de/diskussion/1329784-1-10/molecular-partners-grosse-hoffnung-covid-19-medikament
The ATH should be about CHF 38.40 what is + CHF 10 from CHF 28.40.
These are about 35% more to go from here...
I think, a "real" new ATH will be reached (very) soon!
15 Mar 2021 10:03 AM
(adds details, analyst commentary and stock price)
Zurich (awp) - Molecular Partners announced on Monday that its experimental Covid-19 ensovibep pneumonia darpin (MP0420 not long ago) has been included in the Activ-3 program of Phase III clinical studies conducted by the National Institutes of Health (NIH) in the US. The aim of this project is to accelerate the therapeutic and vaccine response to the pandemic, the Zurich-based company said in a statement on Monday.
The ensovibep component will initially recruit 300 participants hospitalized with mild to moderate forms of Covid-19 and evaluate the experimental treatment against a placebo, in addition to current treatment standards in the United States, including Gilead's remdesivir. If the results are positive, the NIH plans to enroll an additional 700 patients.
The primary endpoint of this study is the time to sustained recovery over two weeks after hospital discharge.
Molecular Partners' tri-specific antiviral proteins are designed to neutralize the infectious capabilities of Sars-Cov-2. The Zurich-based laboratory asserts that their administration could be effective in both treating and preventing a viral infection.
The Schlieren-based company and its prestigious research partner Novartis recently stated that they had observed an acceptable safety and tolerability profile in a Phase I clinical study in healthy volunteers, with no significant undesirable side effects. A Phase II/III study is expected to be launched in the next three months.
The Swiss Federal Office of Public Health (SFOPH) has pre-ordered 3.2 million doses of ensovibep since August, subject to approval by Swissmedic.
The ups and downs of ensovibep's development are likely to be the main catalyst for Molecular Partners' share price again this year, anticipates Olav Zilian of Mirabaud Securities. The analyst points out that in an ideal world, as in management's hopes, the treatment could be approved in the United States before the end of December.
At 10:05 a.m., Molecular Partners shares were up 5.8% at 22.80 francs, on the provisional podium of an SPI up 0.61%.